Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Topical Insulin Eye Drops in Open-Angle Glaucoma
NCT04118920Phase 1Active, not recruiting
- Sponsor
- Centre hospitalier de l’Université de Montréal
- Start
- Mar 2023
- Primary completion
- Aug 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of regular human insulin in open-angle glaucoma (OAG) (3 arms), sponsored by Centre hospitalier de l’Université de Montréal. Primary endpoints: Rate of hypoglycemia at 6 months, Rate of hypokalemia at 6 months and 2 more. Started Mar 2023; status: active, not recruiting.
02
Drugs
regular human insulin
03
Conditions
open-angle glaucoma (OAG)
Beyond the preview
Go deeper on NCT04118920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04118920.